



# **Prevalence of chronic kidney disease in patients with chronic obstructive pulmonary disease**

*Thesis*

*Submitted for Partial Fulfillment of Master Degree in Chest Diseases & Tuberculosis*

*Presented By*

**Mahmoud Sobhi Hassan Ali**

*M.B.B.Ch.*

*Supervised By*

**Prof. Taher Abd El-Hamid El-Naggar**

*Professor of Chest Diseases and Tuberculosis*

*Faculty of Medicine - Ain Shams University*

**Prof. Samar Hassan Sharkawy**

*Professor of Chest Diseases and Tuberculosis*

*Faculty of Medicine - Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

*2019*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا  
إلا ما علمتنا إنك أنت  
العليم الحكيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,  
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound  
gratitude to **Prof. Taher Abd El-Hamid El-Maggar**,  
Professor of Chest Diseases and Tuberculosis Faculty of  
Medicine - Ain Shams University for his keen guidance, kind  
supervision, valuable advice and continuous encouragement,  
which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and  
thanks to **Prof. Samar Hassan Sharkawy**, Professor of  
Chest Diseases and Tuberculosis Faculty of Medicine - Ain  
Shams University, for his kind care, continuous supervision,  
valuable instructions, constant help and great assistance  
throughout this work.*

*Mahmoud Sobhi Hassan Ali*

# *List of Contents*

Title	Page No.
List of Tables .....	i
List of Figures .....	iii
List of Abbreviations .....	v
Introduction .....	1
Aim of the Work .....	4
Review of Literature	
▪ Chronic Obstructive Pulmonary Disease (COPD) .....	5
▪ Chronic Kidney Disease (CKD) .....	22
▪ Lung Disease in Relation to Kidney Diseases .....	54
▪ Pulmonary-Renal Syndrome .....	62
Patients and Methods .....	70
Results .....	74
Discussion .....	91
Summary .....	97
Conclusion .....	100
Recommendations .....	101
References .....	102
Arabic Summary .....	—

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Stages of Chronic Kidney Disease.....	24
<b>Table (2):</b>	Classification and management of comorbid conditions in CKD .....	29
<b>Table (3):</b>	Additional complications of CKD. ....	40
<b>Table (4):</b>	Blood tests used to assess kidney function and complications of CKD.....	42
<b>Table (5):</b>	Chronic kidney disease: a clinical action plan.....	48
<b>Table (6):</b>	Differential diagnosis of pulmonary renal syndrome.....	64
<b>Table (7):</b>	Demographic presentation of data of study subjects n: (80 subjects).....	75
<b>Table (8):</b>	Number of CKD patients and distribution according to severity.....	76
<b>Table (9):</b>	Comparison between cases and controls regarding sex and age.....	78
<b>Table (10):</b>	Comparison between different demographic data of studied patients.....	80
<b>Table (11):</b>	GFR value between cases and controls.....	81
<b>Table (12):</b>	Comparison between cases and controls regarding CKD prevalence and CKD severity. ....	82
<b>Table (13):</b>	CKD prevalence between cases and controls regarding different demographic data. ....	82
<b>Table (14):</b>	Correlation between FEV1%, FEV/FVC % and creat. presence of CKD. ....	83
<b>Table (15):</b>	Comparison between different demographic data of studied subjects divided in 4 groups.....	84
<b>Table (16):</b>	Comparison between the 4 groups regarding FEV1%, FEV/FVC % and creat. level.....	85

## *List of Tables Cont...*

Table No.	Title	Page No.
<b>Table (17):</b>	Effect of severity of obstruction on GFR.....	86
<b>Table (18):</b>	Effect of severity of obstruction on CKD severity.....	86
<b>Table (19):</b>	Relations between different demographic data and GFR in different groups of COPD.....	87

## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Causes of ESRD in the U.S. ....	25
<b>Figure (2):</b>	Risk factors for the development and progression of CKD .....	28
<b>Figure (3):</b>	Clinical manifestations of CKD. Note how CKD impacts almost every body system .....	33
<b>Figure (4):</b>	Hemodialysis. ....	51
<b>Figure (5):</b>	Peritoneal dialysis.....	52
<b>Figure (6):</b>	Viasys FlowScreen II Spirometer of pulmonology departement of Ain Shams University Hospitals.....	71
<b>Figure (7):</b>	ZAN500 body plethysmograph from Zan Messgeräte GmbH, Oberthulba spirometry. ....	72
<b>Figure (8):</b>	Sex distribution of cases studied. ....	75
<b>Figure (9):</b>	Distribution of CKD in cases studied. ....	76
<b>Figure (10):</b>	CKD severity distribution of cases studied. ....	77
<b>Figure (11):</b>	Sex distribution of cases studied. ....	79
<b>Figure (12):</b>	Comparison between cases and controls regarding age in years.....	79
<b>Figure (13):</b>	Comparison between cases and controls regarding FEV1/FVC ratio.....	80
<b>Figure (14):</b>	Comparison between cases and controls regarding GFR. ....	81
<b>Figure (15):</b>	Relation between body weight and severity of obstruction.....	84
<b>Figure (16):</b>	Correlations between FEV1 and GFR in all patients group. ....	88

## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (17):</b>	Correlations between Creatinine and GFR in all patients group.....	88
<b>Figure (18):</b>	Correlations between body weight and GFR in moderate group. ....	89
<b>Figure (19):</b>	Correlations between FEV1 and GFR in severe group.....	89
<b>Figure (20):</b>	Correlations between Creatinine and GFR in severe group.....	90



## *List of Abbreviations*

Abb.	Full term
AKI.....	Acute kidney injury
Anti-GBM .....	Anti-glomerular basement membrane
AV .....	Arteriovenous
BAL.....	Bronchoalveolar lavage
BMI.....	Body mass index
BOLD.....	Burden of Obstructive Lung Diseases
BUN .....	Blood urea nitrogen
CCPD.....	Continuous cycling peritoneal dialysis
CHF .....	Congestive heart failure
CI .....	Confidence interval
CKD .....	Chronic kidney disease
COPD.....	Chronic obstructive pulmonary disease
CRF .....	Chronic renal failure
CT .....	Computed tomography
CVD .....	Cardiovascular disease
DAH.....	Diffuse alveolar haemorrhage
eGFR.....	Estimated GFR
EPO.....	Erythropoietin
ESA.....	Erythropoiesis-stimulating agent
ESRD .....	End-stage renal disease
GFR.....	Glomerular filtration rate
GN.....	Glomerulonephritis
Hb .....	Hemoglobin
HD.....	Hemodialysis
ICMA .....	Immunochemiluminescent
iPTH .....	Intact PTH

## *List of Abbreviations Cont...*

Abb.	Full term
IRMA .....	Immunoradiometric
IVP .....	Intravenous pyelography
KDIGO .....	Kidney Disease: Improving Global Outcomes
KDOQI .....	Kidney Disease Outcome Quality Initiative
LVH .....	Left ventricular hypertrophy
MDRD .....	Modification of diet in renal disease
MRI .....	Magnetic resonance imaging
NHANES .....	National Health and Nutrition Examination Survey
PAD .....	Peripheral artery disease
PD .....	Peritoneal dialysis
PPIs .....	Proton pump inhibitors
PRS .....	Pulmonary Renal Syndrome
PTH .....	Parathyroid hormone
RAAS .....	Renin-angiotensin-aldosterone system
ROD .....	Renal osteodystrophy
RRT .....	Renal replacement therapy
SE .....	Standard error
SHPT .....	Secondary hyperparathyroidism
TNF- $\alpha$ .....	Tumor necrosis factor-alpha
UACR .....	Urinary albumin-to-creatinine ratio
USRDS .....	United States Renal Data System
WHO .....	World Health Organization

## INTRODUCTION

The incidence and prevalence of chronic kidney disease (CKD) continue to rise worldwide. Increasing age, diabetes, hypertension, and cigarette smoking are well-recognized risk factors for CKD (*Comer et al., 2013*).

Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway inflammation leading to airway obstruction and parenchymal lung destruction (*Barnes, 2014*).

Due to some of the common pathogenic mechanisms, COPD has been associated with increased prevalence of CKD (*Comer et al., 2013*).

Several studies have identified COPD as part of a systemic inflammatory syndrome, (*Georgian Med. 2013*) and reported on the association of comorbidities like lung cancer (*Houghton, 2013*), osteoporosis (*Mapel and Marton, 2013*), progression of atherosclerosis (*Savransky et al., 2007*), and CKD.

Advancing age, diabetes, hypertension, body mass index (BMI) > 35, and cigarette smoking have previously been identified as risk factors for new-onset kidney disease (*Fox et al., 2004*).

Advancing age, history of asthma, severe respiratory problems in childhood, passive smoking, and exposure to

biomass fuel for heating were identified as risk factors for COPD in never-smokers whereas increasing age, history of asthma, and severe respiratory problems in childhood, increasing lifetime exposure to cigarette smoking were identified as independent risk factors for development of COPD in ever-smokers (*Tan et al., 2015*).

Many studies have reported on the high prevalence of CKD in COPD patients across different populations. Moreover, all the studies adjusted for co-variables including age, gender, BMI, and smoking status and this allowed for drawing a conclusion on the independent association of CKD with COPD.

The mechanism by which COPD potentiates the development of CKD remains unclear.

It might be related to the fact that COPD is mainly a disease of the elderly population who have comorbidities such as DM, HTN and CAD, known risk factors associated with CKD. COPD has been associated with systemic inflammation. Pro-inflammatory cytokines, especially tumor necrosis factor-alpha (TNF- $\alpha$ ), play an important role in inflammation (*Barnes, 2009*), and have been shown to increase endothelial inflammation and atherosclerosis. This inflammation is also potentially related to development of diabetes, muscle wasting, and kidney disease. COPD is associated with microalbuminuria and in hypoxemic and hypercapnic patients effective renal flow was found to be reduced.

These changes may be reflective of increased renin-angiotensin system activity seen in COPD patients. In the Multi-Ethnic Study of Atherosclerosis cohort, Harris et al. found an inverse relation between FEV1 and FVC with urinary albumin excretion and urine albumin to urine creatinine ratio (*Harris et al., 2012*).

This finding suggests that systemic microvascular injury may contribute to development of CKD in COPD patients.

Medical management of COPD may contribute to the development of CKD. Studies (*Mapel and Marton, 2013*) showed that COPD patients were more likely to be on potentially nephrotoxic medications than controls. This includes re-current use of antibiotics, as well as PPIs and certain cardiovascular drugs.

## **AIM OF THE WORK**

**T**o study the relationship between COPD using spirometry, and incidence of CKD through measuring kidney functions urea, creatinine, creatinine clearance.

*Chapter 1*

# **CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)**

## **Definition**

**C**hronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

The chronic airflow limitation that is characteristic of COPD is caused by a mixture of small airways disease (e.g., obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person.

These changes do not always occur together, but evolve at different rates over time. Chronic inflammation causes structural changes, narrowing of the small airways and destruction of the lung parenchyma that leads to the loss of alveolar attachments to the small airways and decreases lung elastic recoil. In turn, these changes diminish the ability of the airways to remain open during expiration. A loss of small airways may also contribute to airflow limitation and mucociliary dysfunction is a characteristic feature of the disease. Airflow limitation is usually measured by spirometry as this is the most widely available and reproducible